Biodistribution of small interfering RNA at the organ and cellular levels after lipid nanoparticle-mediated delivery

Journal of Histochemistry and Cytochemistry

Volumn 59, Issue 8, 2011, Pages 727-740

  Shi, Bin ^a   Keough, Ed ^a   Matter, Andrea ^a   Leander, Karen ^a   Young, Stephanie ^a   Carlini, Ed ^a   Sachs, Alan B ^a   Tao, Weikang ^a   Abrams, Marc ^a   Howell, Bonnie ^a   Sepp Lorenzino, Laura ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Biodistribution; Cy5; Delivery; Fish; Hepatocyte; Kupffer cell; Lipid nanoparticle; Lnp; Sinusoid; Sirna

Indexed keywords

MESSENGER RNA; SMALL INTERFERING RNA; SOLID LIPID NANOPARTICLE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BRAIN TISSUE; COMPUTER PROGRAM; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DUODENUM; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE SILENCING; HEART; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; KIDNEY PARENCHYMA; KUPFFER CELL; LIVER; LIVER SINUSOID; LUNG PARENCHYMA; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SPLEEN;

ANIMALS; AUTOANTIGENS; DRUG CARRIERS; FLUORESCENT ANTIBODY TECHNIQUE; GENE KNOCKDOWN TECHNIQUES; IN SITU HYBRIDIZATION, FLUORESCENCE; LIPIDS; MICE; NANOPARTICLES; RIBONUCLEOPROTEINS; RNA, MESSENGER; RNA, SMALL INTERFERING; TISSUE DISTRIBUTION;

MUS; PRIMATES; RODENTIA;

EID: 80051711280     PISSN: 00221554     EISSN: None     Source Type: Journal    
DOI: 10.1369/0022155411410885     Document Type: Article

References (76)

1. Abrams MT, Koser ML, Seitzer J, Williams SC, DiPietro MA, Wang W, Shaw AW, Mao X, Jadhav V, Davide JP, et al. 2010. Evaluation of efficacy, biodistribution, and inflammation for a potent siRNA nanoparticle: effect of dexamethasone co-treatment. Mol Ther. 18:171-180.
2. Ali MM, Yoo B, Pagel MD. 2009. Tracking the relative in vivo pharmacokinetics of nanoparticles with PARACEST MRI. Mol Pharm. 6:1409-1416.
3. Aouadi M, Tesz GJ, Nicoloro SM, Wang M, Chouinard M, Soto E, Ostroff GR, Czech MP. 2009. Orally delivered siRNA targeting macrophage Map4k4 suppresses systemic inflammation. Nature. 458:1180-1184.
4. Baldwin L, Flanagan BF, Hunt JA. 2005. Flow cytometric measurement of phagocytosis reveals a role for C3b in metal particle uptake by phagocytes. J Biomed Mater Res A. 73:80-85.
5. Baratta JL, Ngo A, Lopez B, Kasabwalla N, Longmuir KJ, Robertson RT. 2009. Cellular organization of normal mouse liver: a histological, quantitative immunocytochemical, and fine structural analysis. Histochem Cell Biol. 131:713-726.
6. Bartlett DW, Su H, Hildebrandt IJ, Weber WA, Davis ME. 2007. Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc Natl Acad Sci U S A. 104:15549-15554.
7. Cattori V, van Montfoort JE, Stieger B, Landmann L, Meijer DK, Winterhalter KH, Meier PJ, Hagenbuch B. 2001. Localization of organic anion transporting polypeptide 4 (Oatp4) in rat liver and comparison of its substrate specificity with Oatp1, Oatp2 and Oatp3. Pflugers Arch. 443:188-195.
8. Chambers JC, Keene JD. 1985. Isolation and analysis of cDNA clones expressing human lupus La antigen. Proc Natl Acad Sci U S A. 82:2115-2119.
9. Chan EK, Sullivan KF, Fox RI, Tan EM. 1989. Sjogren's syndromenuclear antigen B (La): cDNA cloning, structural domains, and autoepitopes. J Autoimmun. 2:321-327.
10. Chan EK, Sullivan KF, Tan EM. 1989. Ribonucleoprotein SS-B/ La belongs to a protein family with consensus sequences for RNA-binding. Nucleic Acids Res. 17:2233-2244.
11. Chen Y, Huang L. 2008. Tumor-targeted delivery of siRNA by non-viral vector: safe and effective cancer therapy. Expert Opin Drug Deliv. 5:1301-1311.
12. Cheng A, Li M, Liang Y, Wang Y, Wong L, Chen C, Vlassov AV, Magdaleno S. 2009. Stem-loop RT-PCR quantification of siRNAs in vitro and in vivo. Oligonucleotides. 19:203-208.
13. Chu PG, Ishizawa S, Wu E, Weiss LM. 2002. Hepatocyte antigen as a marker of hepatocellular carcinoma: an immunohistochemical comparison to carcinoembryonic antigen, CD10, and alpha-fetoprotein. Am J Surg Pathol. 26:978-988.
14. Cooper JA. 1987. Effects of cytochalasin and phalloidin on actin. J Cell Biol. 105:1473-1478.
15. Crowther C, Ely A, Hornby J, Mufamadi S, Salazar F, Marion P, Arbuthnot P. 2008. Efficient inhibition of hepatitis B virus replication in vivo, using polyethylene glycol-modified adenovirus vectors. Hum Gene Ther. 19:1325-1331.
16. Dambach DM, Watson LM, Gray KR, Durham SK, Laskin DL. 2002. Role of CCR2 in macrophage migration into the liver during acetaminophen-induced hepatotoxicity in the mouse. Hepatology. 35:1093-1103.
17. Dassie JP, Liu XY, Thomas GS, Whitaker RM, Thiel KW, Stockdale KR, Meyerholz DK, McCaffrey AP, McNamara JO 2nd, Giangrande PH. 2009. Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMAexpressing tumors. Nat Biotechnol. 27:839-849.
18. Davis ME, Zuckerman JE, Choi CH, Seligson D, Tolcher A, Alabi CA, Yen Y, Heidel JD, Ribas A. 2010. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature. 464:1067-1070.
19. Dimitrova M, Affolter C, Meyer F, Nguyen I, Richard DG, Schuster C, Bartenschlager R, Voegel JC, Ogier J, Baumert TF. 2008. Sustained delivery of siRNAs targeting viral infection by cell-degradable multilayered polyelectrolyte films. Proc Natl Acad Sci U S A. 105:16320-16325.
20. Fallon MB, Brecher AR, Balda MS, Matter K, Anderson JM. 1995. Altered hepatic localization and expression of occludin after common bile duct ligation. Am J Physiol. 269:C1057-C1062.
21. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. 1998. Potent and specific genetic interference by doublestranded RNA in Caenorhabditis elegans. Nature. 391:806-811.
22. Galarneau L, Loranger A, Gilbert S, Marceau N. 2007. Keratins modulate hepatic cell adhesion, size and G1/S transition. Exp Cell Res. 313:179-194.
23. Gao S, Dagnaes-Hansen F, Nielsen EJ, Wengel J, Besenbacher F, Howard KA, Kjems J. 2009. The effect of chemical modification and nanoparticle formulation on stability and biodistribution of siRNA in mice. Mol Ther. 17:1225-1233.
24. Gaucher G, Asahina K, Wang J, Leroux JC. 2009. Effect of poly(N-vinyl-pyrrolidone)-block-poly(D,L-lactide) as coating agent on the opsonization, phagocytosis, and pharmacokinetics of biodegradable nanoparticles. Biomacromolecules. 10:408-416.
25. Guibinga GH, Song S, Loring J, Friedmann T. 2008. Characterization of the gene delivery properties of baculoviral-based virosomal vectors. J Virol Methods. 148:277-282.
26. Harashima M, Harada K, Ito Y, Hyuga M, Seki T, Ariga T, Yamaguchi T, Niimi S. 2008. Annexin A3 expression increases in hepatocytes and is regulated by hepatocyte growth factor in rat liver regeneration. J Biochem. 143:537-545.
27. Helmy KY, Katschke KJ Jr, Gorgani NN, Kljavin NM, Elliott JM, Diehl L, Scales SJ, Ghilardi N, van Lookeren Campagne M. 2006. CRIg: a macrophage complement receptor required for phagocytosis of circulating pathogens. Cell. 124:915-927.
28. Hiraoka A, Horiike N, Akbar SM, Michitaka K, Matsuyama T,Onji M. 2005. Expression of CD163 in the liver of patients with viral hepatitis. Pathol Res Pract. 201:379-384.
29. Hirschfield GM, Herbert J, Kahan MC, Pepys MB. 2003. Human C-reactive protein does not protect against acute lipopolysaccharide challenge in mice. J Immunol. 171:6046-6051.
30. Holness CL, Simmons DL. 1993. Molecular cloning of CD68, a human macrophage marker related to lysosomal glycoproteins. Blood. 81:1607-1613.
31. Holub M, Cheng CW, Mott S, Wintermeyer P, van Rooijen N, Gregory SH. 2009. Neutrophils sequestered in the liver suppress the proinflammatory response of Kupffer cells to systemic bacterial infection. J Immunol. 183:3309-3316.
32. Jafari M, Chen P. 2009. Peptide mediated siRNA delivery. Curr Top Med Chem. 9:1088-1097.
33. Kawakami S. 2008. [Development and application of glycosylated particulate carriers for delivery of nucleic acid medicine]. Yakugaku Zasshi. 128:1743-1749.
34. Kim Y, Tewari M, Pajerowski JD, Cai S, Sen S, Williams JH, Sirsi SR, Lutz GJ, Discher DE. 2009. Polymersome delivery of siRNA and antisense oligonucleotides. J Control Release. 134:132-140.
35. Kinoshita M, Uchida T, Sato A, Nakashima M, Nakashima H, Shono S, Habu Y, Miyazaki H, Hiroi S, Seki S. 2010. Characterization of two F4/80-positive Kupffer cell subsets by their function and phenotype in mice. J Hepatol. 53:903-910.
36. Lapis K, Zalatnai A, Timar F, Thorgeirsson UP. 1995. Quantitative evaluation of lysozyme- and CD68-positive Kupffer cells in diethylnitrosamine-induced hepatocellular carcinomas in monkeys. Carcinogenesis. 16:3083-3085.
37. Lee RC, Feinbaum RL, Ambros V. 1993. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 75:843-854.
38. Leuschner PJ, Ameres SL, Kueng S, Martinez J. 2006. Cleavage of the siRNA passenger strand during RISC assembly in human cells. EMBO Rep. 7:314-320.
39. Li L, Shen Y. 2009. Overcoming obstacles to develop effective and safe siRNA therapeutics. Expert Opin Biol Ther. 9:609-619
40. Lian G, Wang C, Teng C, Zhang C, Du L, Zhong Q, Miao C, Ding M, Deng H. 2006. Failure of hepatocyte marker-expressing hematopoietic progenitor cells to efficiently convert into hepatocytes in vitro. Exp Hematol. 34:348-358.
41. Liu G, Amin S, Okuhama NN, Liao G, Mingle LA. 2006. A quantitative evaluation of peroxidase inhibitors for tyramide signal amplification mediated cytochemistry and histochemistry. Histochem Cell Biol. 126:283-291.
42. Lu JJ, Langer R, Chen J. 2009. A novel mechanism is involved in cationic lipid-mediated functional siRNA delivery. MolPharm. 6:763-771.
43. Luster MI, Germolec DR, Yoshida T, Kayama F, Thompson M. 1994. Endotoxin-induced cytokine gene expression and excretion in the liver. Hepatology. 19:480-488.
44. Malarkey DE, Johnson K, Ryan L, Boorman G, Maronpot RR. 2005. New insights into functional aspects of liver morphology. Toxicol Pathol. 33:27-34.
45. Manjunath N, Wu H, Subramanya S, Shankar P. 2009. Lentiviral delivery of short hairpin RNAs. Adv Drug Deliv Rev. 61:732-745
46. Masaki T, Tokuda M, Fujimura T, Ohnishi M, Tai Y, Miyamoto K, Itano T, Matsui H, Watanabe S, Sogawa K, et al. 1994. Involvement of annexin I and annexin II in hepatocyte proliferation: can annexins I and II be markers for proliferative hepatocytes? Hepatology. 20:425-435.
47. Matranga C, Tomari Y, Shin C, Bartel DP, Zamore PD. 2005. Passenger-strand cleavage facilitates assembly of siRNA into Ago2-containing RNAi enzyme complexes. Cell. 123:607-620.
48. McNamara JO, 2nd, Andrechek ER, Wang Y, Viles KD, Rempel RE, Gilboa E, Sullenger BA, Giangrande PH. 2006. Cell typespecific delivery of siRNAs with aptamer-siRNA chimeras. Nat Biotechnol. 24:1005-1015.
49. Merkel OM, Librizzi D, Pfestroff A, Schurrat T, Behe M, Kissel T. 2009. In vivo SPECT and real-time gamma camera imaging of biodistribution and pharmacokinetics of siRNA delivery using an optimized radiolabeling and purification procedure. Bioconjug Chem. 20:174-182.
50. Merkel OM, Librizzi D, Pfestroff A, Schurrat T, Buyens K, Sanders NN, De Smedt SC, Behe M, Kissel T. 2009. Stability of siRNA polyplexes from poly(ethylenimine) and poly(ethylenimine)- g-poly(ethylene glycol) under in vivo conditions: effects on pharmacokinetics and biodistribution measured by fluorescence fluctuation spectroscopy and single photon emission computed tomography (SPECT) imaging. J Control Release. 138:148-159.
51. Morin A, Gallou-Kabani C, Mathieu JR, Cabon F. 2009. Systemic delivery and quantification of unformulated interfering RNAs in vivo. Curr Top Med Chem. 9:1117-1129.
52. Morrissey DV, Blanchard K, Shaw L, Jensen K, Lockridge JA, Dickinson B, McSwiggen JA, Vargeese C, Bowman K, Shaffer CS, et al. 2005. Activity of stabilized short interfering RNA in a mouse model of hepatitis B virus replication. Hepatology. 41:1349-1356.
53. Morrissey DV, Lockridge JA, Shaw L, Blanchard K, Jensen K, Breen W, Hartsough K, Machemer L, Radka S, Jadhav V, et al. 2005. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol. 23:1002-1007.
54. Nagayama S, Ogawara K, Fukuoka Y, Higaki K, Kimura T. 2007. Time-dependent changes in opsonin amount associated on nanoparticles alter their hepatic uptake characteristics. Int J Pharm. 342:215-221.
55. Ogawara K, Higaki K, Kimura T. 2002. Major determinants in hepatic disposition of polystyrene nanospheres: implication for rational design of particulate drug carriers. Crit Rev Ther Drug Carrier Syst. 19:277-306.
56. Owens DE, 3rd, Peppas NA. 2006. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm. 307:93-102.
57. Peer D, Shimaoka M. 2009. Systemic siRNA delivery to leukocyteimplicated diseases. Cell Cycle. 8:853-859.
58. Pena JT, Sohn-Lee C, Rouhanifard SH, Ludwig J, Hafner M, ihailovic A, Lim C, Holoch D, Berninger P, Zavolan M, et al. 2009. MiRNA in situ hybridization in formaldehyde and EDC-fixed tissues. Nat Methods. 6:139-141.
59. Ramprasad MP, Fischer W, Witztum JL, Sambrano GR, Quehenberger O, Steinberg D. 1995. The 94- to 97-kDa mouse macrophage membrane protein that recognizes oxidized low density lipoprotein and phosphatidylserine-rich liposomes is identical to macrosialin, the mouse homologue of human CD68. Proc Natl Acad Sci U S A. 92:9580-9584.
60. Rozema DB, Lewis DL, Wakefield DH, Wong SC, Klein JJ, Roesch PL, Bertin SL, Reppen TW, Chu Q, Blokhin AV, et al. 2007. Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes. Proc Natl Acad Sci U S A. 104:12982-12987.
61. Schiedner G, Hertel S, Johnston M, Dries V, van Rooijen N, Kochanek S. 2003. Selective depletion or blockade of Kupffer cells leads to enhanced and prolonged hepatic transgene expression using highcapacity adenoviral vectors. Mol Ther. 7:35-43.
62. Seitzer J, Zhang H, Koser M, Pei Y, Abrams M. 2010. Effect of biological matrix and sample preparation on qPCR quantitation of siRNA drugs in animal tissues. J Pharmacol Toxicol Methods. 63:168-173.
63. Sekine S, Ogawa R, McManus MT, Kanai Y, Hebrok M. 2009. Dicer is required for proper liver zonation. J Pathol. 219:365-372.
64. Sepp-Lorenzino L, Ruddy M. 2008. Challenges and opportunities for local and systemic delivery of siRNA and antisense oligonucleotides. Clin Pharmacol Ther. 84:628-632.
65. Shan X, Yuan Y, Liu C, Tao X, Sheng Y, Xu F. 2009. Influence of PEG chain on the complement activation suppression and longevity in vivo prolongation of the PCL biomedical nanoparticles. Biomed Microdevices. 11:1187-1194.
66. Shim MS, Kwon YJ. 2010. Efficient and targeted delivery of siRNA in vivo. FEBS J. 277:4814-4827.
67. Silahtaroglu AN, Nolting D, Dyrskjot L, Berezikov E, Moller M, Tommerup N, Kauppinen S. 2007. Detection of microRNAs in frozen tissue sections by fluorescence in situ hybridization using locked nucleic acid probes and tyramide signal amplification. Nat Protoc. 2:2520-2528.
68. Smit MJ, Duursma AM, Bouma JM, Gruber M. 1987. Receptormediated endocytosis of lactate dehydrogenase M4 by liver macrophages: a mechanism for elimination of enzymes from plasma: evidence for competition by creatine kinase MM, adenylate kinase, malate, and alcohol dehydrogenase. J Biol Chem. 262:13020-13026.
69. Smith JS, Xu Z, Byrnes AP. 2008. A quantitative assay for measuring clearance of adenovirus vectors by Kupffer cells. J Virol Methods. 147:54-60.
70. Snoeys J, Lievens J, Wisse E, Jacobs F, Duimel H, Collen D, Frederik P, De Geest B. 2007. Species differences in transgene DNA uptake in hepatocytes after adenoviral transfer correlate with the size of endothelial fenestrae. Gene Ther. 14:604-612.
71. Soutschek J, Akinc A, Bramlage B, Charisse K, Constien R, Donoghue M, Elbashir S, Geick A, Hadwiger P, Harborth J, et al. 2004. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature. 432: 173-178.
72. Tao W, Davide JP, Cai M, Zhang GJ, South VJ, Matter A, Ng B, Zhang Y, Sepp-Lorenzino L. 2010. Noninvasive imaging of lipid nanoparticle-mediated systemic delivery of smallinterfering RNA to the liver. Mol Ther. 18:1657-1666.
73. Thiel KW, Giangrande PH. 2009. Therapeutic applications of DNA and RNA aptamers. Oligonucleotides. 19:209-222.
74. Tseng YC, Mozumdar S, Huang L. 2009. Lipid-based systemic delivery of siRNA. Adv Drug Deliv Rev. 61:721-731.
75. White PJ. 2008. Barriers to successful delivery of short interfering RNA after systemic administration. Clin Exp Pharmacol Physiol. 35:1371-1376.
76. Yavuz MS, Cheng Y, Chen J, Cobley CM, Zhang Q, Rycenga M, Xie J, Kim C, Song KH, Schwartz AG, et al. 2009. Gold nanocages covered by smart polymers for controlled release with near-infrared light. Nat Mater. 8:935-939.